Free shipping on all orders over $ 500

SGI-110

Cat. No. M3009
SGI-110 Structure
Synonym:

SGI-110 sodium; S-110 sodium

Size Price Availability
10mg USD 220  USD220 Custom Synthesis
50mg USD 780  USD780 Custom Synthesis
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

SGI-110 (S-110) is a stable and potent inhibitor for DNA methylation, inhibits DNMT1 when SGI-110 is activated by phosphorylation and incorporated into DNA.

Chemical Information
Molecular Weight 579.39
Formula C18H23N9O10P.Na
CAS Number 929904-85-8
Form Solid
Solubility (25°C) DMSO
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Caner Saygin, et al. Current and emerging strategies for management of myelodysplastic syndromes

[2] Jessica Dittmann, et al. Next-generation hypomethylating agent SGI-110 primes acute myeloid leukemia cells to IAP antagonist by activating extrinsic and intrinsic apoptosis pathways

[3] Georgina S Daher-Reyes, et al. Guadecitabine (SGI-110): an investigational drug for the treatment of myelodysplastic syndrome and acute myeloid leukemia

[4] Yuting Kuang, et al. Guadecitabine (SGI-110) priming sensitizes hepatocellular carcinoma cells to oxaliplatin

[5] Carmen S Tellez, et al. SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome

Related DNA Methyltransferase Products
(S)-GSK-3685032

(S)-GSK-3685032 is the inactive isomer of GSK-3685032.GSK-3685032 is a non-time-dependent, non-covalent, first-in-class, reversible selective inhibitor of DNMT1 with an IC50 value of 0.036 μM.GSK-3685032 induces DNA GSK-3685032 induces loss of DNA methylation, transcriptional activation and cancer cell growth inhibition.

(R)-GSK-3685032

(R)-GSK-3685032 is the R-isomer of GSK-3685032.GSK-3685032 is a non-time-dependent, non-covalent, first-in-class, reversible selective inhibitor of DNMT1 with an IC50 value of 0.036 μM.GSK-3685032 induces DNA GSK-3685032 induces loss of DNA methylation, transcriptional activation and cancer cell growth inhibition.

DNMT-IN-1

DNMT-IN-1 is a potent DNMT inhibitor with an EC50 value of 3.2 µM.

DNMT2-IN-1

DNMT2-IN-1 is a potent and selective DNMT2 (DNA methyltransferase 2) inhibitor with an IC50 value of 1.2 μM, and has the potential for mental and metabolic disorders or cancer research.

Guadecitabine

Guadecitabine (SGI-110) is a second-generation DNA methyltransferases (DNMT) inhibitor for research of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

  Catalog
Abmole Inhibitor Catalog




Keywords: SGI-110, SGI-110 sodium; S-110 sodium supplier, DNA Methyltransferase, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.